Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E24.84 EPS (ttm)1.42 Insider Own0.10% Shs Outstand6.30B Perf Week0.66%
Market Cap222.02B Forward P/E15.73 EPS next Y2.24 Insider Trans-7.29% Shs Float6.15B Perf Month2.83%
Income9.09B PEG8.01 EPS next Q0.49 Inst Own73.90% Short Float2.08% Perf Quarter9.65%
Sales49.61B P/S4.48 EPS this Y-14.50% Inst Trans-0.12% Short Ratio4.40 Perf Half Y26.82%
Book/sh11.32 P/B3.12 EPS next Y8.05% ROA6.70% Target Price36.32 Perf Year18.95%
Cash/sh5.74 P/C6.15 EPS next 5Y3.10% ROE15.10% 52W Range27.04 - 35.53 Perf YTD14.23%
Dividend1.12 P/FCF25.55 EPS past 5Y3.10% ROI8.90% 52W High-0.73% Beta0.79
Dividend %3.18% Quick Ratio2.40 Sales past 5Y0.10% Gross Margin80.80% 52W Low30.46% ATR0.49
Employees78300 Current Ratio2.70 Sales Q/Q-3.20% Oper. Margin29.20% RSI (14)57.24 Volatility1.21% 1.32%
OptionableYes Debt/Eq0.51 EPS Q/Q-50.00% Profit Margin23.10% Rel Volume0.78 Prev Close35.36
ShortableYes LT Debt/Eq0.44 EarningsApr 28 BMO Payout57.50% Avg Volume29.13M Price35.27
Recom2.20 SMA201.20% SMA502.04% SMA20013.50% Volume22,798,582 Change-0.25%
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-15-13Reiterated Barclays Equal Weight $25 → $32
Jan-30-13Reiterated UBS Buy $29 → $31
Jan-30-13Reiterated Argus Buy $28 → $32
Jan-22-13Reiterated Barclays Equal Weight $24 → $25
Nov-27-12Downgrade MKM Partners Buy → Neutral $29 → $25
Oct-05-12Reiterated MKM Partners Buy $27 → $29
Nov-01-11Downgrade Standpoint Research Buy → Hold
Oct-07-11Initiated MKM Partners Buy $20.50
Sep-14-11Downgrade Barclays Capital Overweight → Equal Weight $21 → $19
Aug-10-11Upgrade Argus Hold → Buy $21
Aug-05-11Upgrade Standpoint Research Hold → Buy $21
Mar-14-11Downgrade Standpoint Research Buy → Hold
Nov-03-10Downgrade Argus Buy → Hold
May-21-10Initiated Jefferies Buy $17.80
Dec-16-09Initiated UBS Buy
Apr-27-09Initiated Standpoint Research Buy $20
Feb-12-09Upgrade Leerink Swann Mkt Perform → Outperform
Apr-24-15 05:14PM  Inversion Deals Arent Dead, Theyre Just More Low-Key: Real M&A at Bloomberg
04:28PM  Stocks rise on tech earnings; Nasdaq adds to record AP
02:44PM  Johnson & Johnson Posts Earnings, Lowers EPS Guidance on April 14
02:18PM  The Fed, Apple and Kentucky Derby: What's on tap next week
01:28PM  Business events scheduled for the coming week
10:58AM  Pfizer Inc. (PFE), Anthem Inc (ANTM), Aetna Inc (AET): Swedish Fund, Healthinvests Top Bullish Picks In First Quarter at Insider Monkey
10:35AM  Nasdaq Takes Lead In Mixed Open; Microsoft Surges, Biogen Dives at Investor's Business Daily
04:23AM  AstraZeneca looks beyond Nexium hit with new cancer deals
02:19AM  AstraZeneca hit by copycat Nexium and strong dollar in Q1 Reuters
Apr-23-15 07:07PM  Merck Gets a Boost of 69% in AQR Capitals Portfolio
02:46PM  Pfizer Hosts Annual Meeting Of Shareholders at noodls
02:07PM  Pfizer Hosts Annual Meeting Of Shareholders Business Wire
02:01PM  What Are the Conditions of the Mylan-Teva Deal?
12:06PM  AQR Capital Enhances Pfizer Holdings by 33%
10:00AM  Drug Companies Pin Hopes On TrialReach To Enroll Patients In Clinical Trials Faster at Forbes
07:39AM  LLY CFO: Here's what's driving profits
03:06AM  AQR Capital More Than Doubles its Holdings in Gilead Sciences
12:36AM  Meet Pharmas Newest Movers and Shakers at The Wall Street Journal
Apr-22-15 09:22PM  Meet Pharma's Newest Movers and Shakers at The Wall Street Journal
05:58PM  Pfizer's Cancer Drug Meets First Primary Endpoint in Phase III - Analyst Blog
05:24PM  Beat The Market Twice: 5 Top Dividend Stock Winners at Investor's Business Daily
02:33PM  The MylanTeva Deal: Arbitrage Spread Analysis
02:33PM  Teva Pharmaceuticals Makes a Hostile Bid for Mylan
09:35AM  Teva-Mylan-Perrigo: Merger Mania In Pursuit Of Generic Margins at Forbes
06:14AM  Are M&A Replacing R&D In Pharma? at Forbes
05:02AM  Roche more confident in beating Alzheimer's after Biogen data
04:30AM  Boehringer posts flat earnings on stagnant Pradaxa sales Reuters
Apr-21-15 06:17PM  U.S. cancer institute, software firm reach deals in Cuba Reuters
06:11PM  Pfizer: Juicy Dividend, Strong Pipeline, Big Gains at Barrons.com
04:53PM  Pfizer Earnings Preview: 5 Things You Need to Know at Investopedia
04:50PM  Merck KGaA-Pfizer Start First Cancer Registration Study - Analyst Blog
02:14PM  Mylans Three-Way Deal Dance Is a Win for Shareholders: Real M&A at Bloomberg
12:15PM  Mylan's Lesson from Deal-Making's Past at The Wall Street Journal
12:06PM  Pfizer says leukemia drug met 1 goal in study
10:25AM  Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI® (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer at noodls
10:00AM  Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI® (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer Business Wire
09:30AM  AstraZeneca drug Lynparza shows promise in prostate cancer trial
08:11AM  Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia at noodls
08:00AM  Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia Business Wire
Apr-20-15 06:07PM  AQR Capital Ups Stake in Johnson and Johnson
04:08PM  MylanPerrigo Merger: What Are the Long-Term Growth Drivers?
10:55AM  Cuomo's headed for Cuba, but don't expect a 'Nixon goes to China' moment at bizjournals.com
09:30AM  The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, iShares U.S. Pharmaceuticals and Market Vectors Pharmaceutical - Press Releases
08:10AM  Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Study with Avelumab* in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer at noodls
08:02AM  Global Strategic Partners Merck and Pfizer Initiate Phase III Study with Avelumab in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer at noodls
08:00AM  Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Study with Avelumab* in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer Business Wire
Apr-19-15 02:38PM  NY's Cuomo to be first gov. to visit Cuba as ties reopen
02:07AM  Future UK Labour government will give workers a say on the boss's pay at Financial Times
Apr-17-15 07:36PM  Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog
06:40PM  Pfizer Wins First Trial Over Zoloft Birth-Defect Claims
05:34PM  Pfizer wins first U.S. trial over Zoloft birth-defect risk
05:17PM  Pfizer Wins First Trial Over Zoloft Birth-Defect Claims at Bloomberg
04:46PM  Teva Getting Serious About Mylan Bid, Says Report at Investor's Business Daily
02:27PM  Pfizer Jury Told Zoloft Risks Known But Hidden From Patients at Bloomberg
01:24PM  A Beginner's Guide to Pharma ETFs - ETF News And Commentary
12:19PM  Dorset Management Made a Bundle By Betting on Biotech and Energy; More Profits to Come? at Insider Monkey
11:05AM  Why Supposedly Abuse-Proof Pills Won't Stop Opioid Overdose Deaths at Forbes
10:09AM  Maverick Capital Increases Stake in Novartis
08:10AM  The 5 Best DJIA Stocks of 2015 With More Upside Expected at 24/7 Wall St.
Apr-16-15 09:53PM  Is This Pfizer's Next Mega-Blockbuster Drug? at Investopedia
05:26PM  Biotech giants present new data
05:00PM  Pfizer's Ibrance Study Stopped Early on Favorable Data - Analyst Blog
04:59PM  Antitrust Protections Hardly Provide a 'Road Map' for Merger Challenges, Regulators Say at TheStreet
03:44PM  Big pharma M&A may keep booming, CEOs say at CNBC
02:54PM  Pfizer Invites Public to Listen to Webcast of April 23 Annual Meeting of Shareholders at noodls
02:26PM  Pfizer Invites Public to Listen to Webcast of April 23 Annual Meeting of Shareholders Business Wire
02:00PM  Boston Business Journal's 2015 Pacesetters celebrates the region's fastest-growing companies (photo gallery) at bizjournals.com
01:53PM  Need to change the laws on corporate tax: Pfizer CEO
10:40AM  MTNB: Matinas' Pipeline Is Ready To Shine
09:30AM  The Zacks Analyst Blog Highlights: Pfizer, Pharmacyclics, Geron, Anthera Pharmaceuticals and Cytori Therapeutics - Press Releases
08:48AM  Pfizer Launches 2014 Integrated Annual Review at noodls
08:30AM  Pfizer Launches 2014 Integrated Annual Review Business Wire
Apr-15-15 02:41PM  AbbVie: Strong Data, Once Daily Dose 'Necessary to Ensure Strong Commercial Success' at Barrons.com
12:58PM  Approved Pfizer breast cancer drug impresses in latest study
12:01PM  Oil breaks higher
11:49AM  Pfizer, Biogen, AbbVie Get Good Drug-Trial News at Investor's Business Daily
09:44AM  Pfizer Breast-Cancer Study Meets Primary Endpoint at The Wall Street Journal
09:29AM  AstraZeneca science is on the move, one year on from Pfizer bid
08:13AM  Pfizer Announces PALOMA-3 Trial For IBRANCE® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy at noodls
08:00AM  Pfizer Announces PALOMA-3 Trial For IBRANCE® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy Business Wire
Apr-14-15 07:15PM  Mylan Settles Patent Litigation Related to Pfizer's Viagra - Analyst Blog
04:16PM  Johnson & Johnson, Pfizer and Zimmer Holdings are Top Stock Picks at TheStreet
01:30PM  Five companies that may be looking to buy Ariad Pharmaceuticals at bizjournals.com
11:06AM  Lone Pine Capital Sells Its Stake in Actavis
08:07AM  JNJ growth driven by pharma biz: Expert
01:00AM  Banks see talent flee amid healthcare M&A boom Reuters
Apr-13-15 04:01PM  The 4 Stocks That Sank the Dow on Monday at 24/7 Wall St.
03:33PM  Mylan settles Viagra patent litigation with Pfizer
12:41PM  Pfizer Inc. (PFE) Helped Kahn Brothers Beat the Market Despite BlackBerry Ltd (BBRY) Losses at Insider Monkey
09:50AM  Pfizer Accused of Knowing Zoloft Posed Birth Risk at Bloomberg
06:55AM  The 5 Most Shorted NYSE Stocks at the End of Q1 at 24/7 Wall St.
04:36AM  Polio Vaccine Found "Safe And Effective" 60 Years Ago: What Would Salk Think Today? at Forbes
Apr-10-15 04:36PM  Biotech Ligand Gets Sweeter Deal From Partner Viking at Investor's Business Daily
12:17PM  Valeant VPs $50.6 Million Pay Second to Apple Among Non-CEOs at Bloomberg
12:01PM  Pfizer (PFE) Stock Is the 'Chart of the Day' at TheStreet
08:40AM  PharmalotPharmalittleGood Morning: We're Catching up on Eisai, HepC Research, Pfizer and Ebola at The Wall Street Journal
Apr-09-15 04:01PM  The 4 Stocks That Lifted the Dow on Thursday at 24/7 Wall St.
11:34AM  Buy These 5 Blue-Chip Stocks for Breakout Gains in April at TheStreet
11:30AM  Royal Dutch/Shell Deal Is More Evidence Corporate America Is Losing Bigness Bragging Rights at Forbes
10:40AM  Everything is up for grabs in pharmaceuticals: Pro
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women's/men's health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has collaboration with BIND Therapeutics, Inc. to develop and commercialize multiple Accurins. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUSMAN SALLYExecutive Vice PresidentMar 12Sale34.0046,1791,570,086150,899Mar 13 10:39 AM
Dolsten MikaelPresident R&DMar 05Sale34.4658,2982,009,152355,911Mar 06 07:32 PM
READ IAN CChairman & CEOMar 05Sale34.6267,5002,336,7931,408,457Mar 06 07:19 PM
OLSON LAURIE JExecutive Vice PresidentFeb 25Option Exercise17.6921,115373,52481,240Feb 27 06:49 PM
HILL CHARLES HExecutive Vice PresidentFeb 25Option Exercise17.6922,523398,432121,572Feb 27 06:42 PM
JOHNSON RADY AExecutive Vice PresidentFeb 25Option Exercise17.6919,426343,64656,250Feb 27 06:42 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 25Option Exercise17.6932,855581,205141,441Feb 27 06:42 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 25Option Exercise17.69101,3511,792,899227,982Feb 27 06:42 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 25Option Exercise17.6923,649418,35188,933Feb 27 06:42 PM
READ IAN CChairman & CEOFeb 25Option Exercise17.69197,0723,486,2041,568,718Feb 27 06:50 PM
SUSMAN SALLYExecutive Vice PresidentFeb 25Option Exercise17.6995,7211,693,304261,233Feb 27 06:56 PM
YOUNG JOHN DGroup PresidentFeb 25Option Exercise17.6949,364873,249159,673Feb 27 06:56 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Option Exercise26.20104,0002,724,800288,775Feb 17 05:50 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Sale34.73104,0003,612,323184,775Feb 17 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 12Sale34.859,000313,66170,252Feb 13 01:50 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.3014,800507,619440,886Feb 12 04:01 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.2380,2002,744,861360,686Feb 12 04:01 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 10Sale33.789,000304,02079,252Feb 11 08:02 PM
LANKLER DOUGLAS MExecutive Vice PresidentDec 31Option Exercise18.1921,413389,502127,673Jan 05 05:17 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerDec 31Option Exercise18.1932,120584,263207,985Jan 05 05:17 PM
HILL CHARLES HExecutive Vice PresidentDec 31Option Exercise18.1926,767486,892126,245Jan 05 05:17 PM
OLSON LAURIE JExecutive Vice PresidentDec 31Option Exercise18.1918,737340,82675,811Jan 05 05:17 PM
YOUNG JOHN DGroup PresidentDec 31Option Exercise18.1926,767486,892128,860Jan 05 05:17 PM
JOHNSON RADY AExecutive Vice PresidentDec 31Option Exercise18.1932,120584,26361,803Jan 05 05:16 PM
MADDALUNA ANTHONY JExecutive Vice PresidentDec 31Option Exercise18.1926,767486,892107,900Jan 05 05:16 PM
BOURLA ALBERTGroup PresidentDec 31Option Exercise18.1916,060292,131113,177Jan 05 05:16 PM
MADDALUNA ANTHONY JExecutive Vice PresidentDec 08Sale32.006,500208,00082,830Dec 09 10:44 AM
HILL CHARLES HExecutive Vice PresidentNov 10Sale30.188,285250,04199,478Nov 10 05:34 PM
YOUNG JOHN DGroup PresidentNov 07Option Exercise26.2021,600565,920123,462Nov 10 05:34 PM
DAMELIO FRANK AExecutive Vice PresidentNov 07Sale29.7807454,687Nov 10 05:34 PM
YOUNG JOHN DGroup PresidentNov 07Sale29.8921,600645,548101,862Nov 10 05:34 PM
READ IAN CChairman & CEOOct 30Option Exercise17.0354,585929,5831,465,906Nov 03 06:23 PM
DAMELIO FRANK AExecutive Vice PresidentOct 30Option Exercise17.0365,5021,115,499501,494Nov 03 06:23 PM
READ IAN CChairman & CEOOct 30Sale29.7667,5002,008,8001,358,862Nov 03 06:23 PM
MADDALUNA ANTHONY JExecutive Vice PresidentOct 29Sale29.562,42571,68388,987Oct 30 06:23 PM
OLSON LAURIE JExecutive Vice PresidentJun 12Option Exercise26.2036,275950,40593,010Jun 13 12:29 PM
OLSON LAURIE JExecutive Vice PresidentJun 12Sale29.5336,2751,071,27856,735Jun 13 12:29 PM